Rafael Holdings, Inc. has filed an 8-K report with the Securities and Exchange Commission on November 9, 2026, to provide access to its November 2026 Investor Presentation. The document, attached as Exhibit 99.1, details the status of the company's lead asset, remibetadex, and its pivotal Phase 3 clinical trial for Niemann-Pick disease type C (NPC).
The presentation outlines the results of the TransportNPC study, which reported topline data in September 2026. The primary analysis of the randomized, double-blind study did not meet its statistical significance threshold. However, the company notes a prespecified analysis of patients who were on miglustat and/or leucine prior to baseline showed a 71% slowing of disease progression compared to placebo, which was statistically significant (p=0.046).
Safety data indicates the drug was generally well-tolerated, though serious adverse events occurred more frequently with remibetadex than with placebo. The presentation also highlights a separate overall survival analysis for infantile-onset NPC, which showed a 94% lower relative mortality risk compared to expanded historical controls.
Regulatory progress is a key focus of the filing. The company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration in October 2026 and requested priority review. The filing includes data from the largest Phase 3 study conducted in NPC patients to date, as well as pediatric substudy results and an overall survival analysis versus external controls.
The company maintains that remibetadex is the only investigational NPC therapy administered intravenously, addressing visceral disease and studied from birth. It holds Orphan Drug Designation in the US and EU, Fast Track Designation in the US, and Rare Pediatric Disease Designation in the US, which provides eligibility for a Priority Review Voucher. The presentation also includes a list of forward-looking statements and associated risks, noting substantial doubt about the company's ability to continue as a going concern and its need for additional capital.
